Application of akr1b10 in the preparation of preparations for diagnosis and treatment of acute myocardial infarction

A technology for acute myocardial infarction and preparation, which is applied in the application field of preparing preparations for diagnosis and treatment of acute myocardial infarction, and achieves the effects of good repeatability, good stability, and simplified quantitative detection process.

Active Publication Date: 2019-03-01
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The inventor performed high-throughput sequencing on the blood samples of 6 cases of acute myocardial infarction and 6 control groups, combined with bioinformatics methods for gene screening, and selected the highly expressed candidate gene AKR1B10 from the genes with obvious differential expression. There is no report related to AKR1B10 and acute myocardial infarction. Further, the inventors carried out molecular verification and confirmed that AKR1B10 is highly expressed in the acute myocardial infarction group, and AKR1B10 inhibitors can be used to prepare drugs for the treatment of acute myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of akr1b10 in the preparation of preparations for diagnosis and treatment of acute myocardial infarction
  • Application of akr1b10 in the preparation of preparations for diagnosis and treatment of acute myocardial infarction
  • Application of akr1b10 in the preparation of preparations for diagnosis and treatment of acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The collection of embodiment 1 case

[0029] From December 2012 to June 2014, 6 patients with initial acute myocardial infarction in the Department of Cardiovascular Medicine of the hospital were selected. The time from the onset of acute myocardial infarction to admission was 0.5-10 hours. The inclusion criteria were in line with the inclusion criteria for acute myocardial infarction announced at the 2012 ESC Congress. All enrolled patients have signed the informed consent. The healthy controls were 6 healthy subjects from the physical examination center of the hospital, who matched the age and gender of the patients in the experimental group, and related diseases were excluded according to the exclusion criteria of the AMI group. Healthy subjects informed and agreed to participate in the study.

[0030] Inclusion criteria:

[0031]Refer to the new version of the global unified definition of myocardial infarction diagnostic criteria announced at the ESC Conference h...

Embodiment 2

[0051] Example 2 High-throughput sequencing and analysis

[0052] RNA extraction is performed on peripheral blood, followed by agarose gel electrophoresis after RNA extraction. From the results of electrophoresis, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome sequencing. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2. The qualified samples were sent to the sequencing company for sequencing. The sequencing platform was the HiSeq 2500 high-throughput sequencing platform of Illumina Company for high-throughput transcriptome deep sequencing. The sequencing company provided the data analysis results and combined with the literature, we screened the differentially expressed gene AKR1B10.

Embodiment 3

[0053] Example 3 AKR1B10 gene expression in peripheral blood of acute myocardial infarction group and control group

[0054] 1. Materials and methods

[0055] 1. Materials

[0056] The peripheral blood of 48 cases of patients with acute myocardial infarction and 45 cases of control group were selected and grouped and numbered. The inclusion and exclusion criteria of the two groups refer to Example 1.

[0057] 2. Method

[0058] 2.1 Extraction of RNA from peripheral blood of patients with acute myocardial infarction and control population White blood cell separation

[0059] (1) Take 2m1 anticoagulated peripheral blood (blood collection time does not exceed 3h);

[0060] (2) Add an equal volume of sterile PBS to the peripheral blood and mix thoroughly to form a cell suspension;

[0061] (3) Add 4ml of lymphocyte separation solution to another centrifuge tube;

[0062] (4) Pipette 4m1 of the cell suspension and gently add it to the surface of the lymphocyte separation medi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of AKR1B10 to preparation of acute myocardial infarction diagnosis and treatment preparation. The inventor carries out high-throughput sequencing analysis on peripheral blood of acute myocardial infarction patients, after candidate genes are selected, molecule cell experiments verify that AKR1B10 is high in expression in an acute myocardial infarction set, and an AKR1B10 inhibitor can be used for preparing medicine for treating acute myocardial infarction. A new monitoring treatment target point for acute myocardial infarction is provided, and the application has important clinical application value.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of AKR1B10 in the preparation of preparations for diagnosis and treatment of acute myocardial infarction. Background technique [0002] Cardiovascular disease is one of the important diseases that threaten human health, especially acute myocardial infarction ((Acute Myocardial Infarction, AMI) has become an important cause of increasing mortality in cardiovascular diseases. Early treatment of AMI plays an important role in the good prognosis of patients. It plays a crucial role. Early, timely and accurate diagnosis and condition estimation of AMI are the necessary conditions for actively taking effective treatment measures and ensuring timely reperfusion of the heart to reduce mortality. Currently, serum biomarkers for clinical diagnosis of AMI are mainly There are creatine kinase isoenzymes, myoglobin and troponin, etc. Although the sensitivity and specificity of the a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883G01N33/68A61K45/00A61K48/00A61K31/7088A61K38/00A61P9/10
CPCA61K31/7088A61K38/00A61K45/00A61K48/005C12Q1/6883G01N33/6893G01N2800/324
Inventor 任静常鹏杨承刚
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap